文献速递血栓与止血MDS 与骨髓增殖性肿瘤

克隆性造血在骨髓与血栓连接中的作用:炎症、克隆性造血与血栓栓塞性疾病

CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease.
PubMed 文献 · Blood Adv · 2025-01-01

动脉粥样硬化血栓形成和静脉血栓栓塞的发病率与预后均与年龄增长强相关。过去十年,意义未明的克隆性造血(CHIP)被确定为心血管疾病的新型生物标志物,由造血系统体细胞突变驱动,在≥70岁人群中估计患病率超过10%。CHIP携带者发生动脉粥样硬化血栓形成的风险持续较高,即使考虑传统心血管危险因素后仍如此,但关联强度在不同研究间存在差异;CHIP与静脉血栓栓塞的关联新近提出,尚需更多研究证实。目前尚无获批疗法改善CHIP携带者的心血管风险,但canakinumab在TET2突变CHIP患者的事后分析中显示出希望,其他抗炎小体药物正在积极开发或评估中。

要点

  • CHIP在≥70岁一般人群中估计患病率超过10%,是年龄依赖的心血管疾病新型生物标志物。
  • CHIP携带者发生动脉粥样硬化血栓形成风险较高,但关联强度在不同研究间存在差异。
  • 目前尚无获批疗法改善CHIP携带者心血管风险,canakinumab在TET2突变CHIP患者事后分析中显示希望。

核心结论

  • CHIP是血栓栓塞性疾病(动脉粥样硬化血栓形成和静脉血栓栓塞)的介质,针对血栓炎症界面的新兴疗法正在开发中。

研究设计与样本

  • 综述, overview of CHIP as a mediator of thromboembolic diseases and emerging therapeutics.

主要发现

  • 在≥70岁一般人群中,CHIP估计患病率超过10%。
  • CHIP携带者发生动脉粥样硬化血栓形成的风险持续较高,即使考虑传统心血管危险因素后仍如此,但关联强度在不同研究间存在差异。
  • 已确立心血管疾病的CHIP个体较非CHIP对照者复发和全因死亡风险更高。
  • CHIP携带与静脉血栓栓塞的关联新近提出,尚需更多研究证实。

临床怎么用

  • 目前尚无获批疗法改善CHIP携带者的心血管风险。
  • canakinumab在TET2突变CHIP患者的事后分析中显示出希望,其他抗炎小体药物正在积极开发或评估中。

局限性

  • CHIP与动脉粥样硬化血栓形成的关联强度在不同研究间存在差异。
  • CHIP与静脉血栓栓塞的关联尚需更多研究证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Both the incidence and prognosis of arterial atherothrombosis and venous thromboembolism are strongly correlated with increasing age. Over the past decade, clonal hematopoiesis of indeterminate potential (CHIP) has been identified as a novel biomarker for cardiovascular disease. Driven by somatic mutations in the hematopoietic system, the epidemiology of CHIP is highly age dependent: among individuals aged ≥70 years in the general population, estimated prevalence of CHIP exceeds 10%. Several additional risk factors for CHIP have emerged in recent years, including smoking, receipt of anticancer therapy, and germ line predispositions. CHIP carriers consistently have higher risk of incident arterial atherothrombosis, even after accounting for traditional cardiovascular risk factors. However, the magnitude of this association varies across studies. In addition, individuals with established cardiovascular disease and CHIP have higher risks of recurrence and all-cause mortality than their non-CHIP counterparts. An association between CHIP carriership and incident venous thromboembolism has recently been made, although additional studies are needed to confirm this finding. No approved therapy exists to modify the cardiovascular risk among CHIP carriers. However, canakinumab showed promise in a post-hoc analyses of patients with TET2-mutated CHIP, and other anti-inflammasome agents are actively under development or evaluation. In this review, we provide an overview of CHIP as a mediator of thromboembolic diseases and discuss emerging therapeutics aimed at intervening on this thrombo-inflammatory nexus.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Todorovski A, Wang TF, Carrier M, et al. CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease. Blood Adv. 2025. PMID: 39561373. doi:10.1182/bloodadvances.2024014430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。